Tag: Lupin Limited
“Biosimilars set to gain as key biologics lose patents by 2030”
Dr Cyrus Karkaria, President-Biotechnology, Lupin Limited shares his views on the current market trends and growth prospects of Indian biosimilars industry, company’s key offerings, ongoing initiatives, and future plans
Lupin acquires Huminsulin from Lilly to enhance Diabetes portfolio
The Huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and children
Lupin secures ISO 14001 and ISO 45001 certification for all Indian...
The achievement highlights commitment to environmental sustainability and workplace safety
Lupin appoints Jeffrey Kindler and Alfonso Zulueta to its Board
Pharmaceutical giant Lupin Limited strengthens its leadership team with the addition of Jeffrey Kindler and Alfonso Zulueta as Independent Directors, enhancing strategic vision and industry insights for future growth
India’s biosimilars industry staring at plethora of opportunities
Between now and 2030, biologic products worth US $170 billion will lose patent protection globally, writes Dr Cyrus Karkaria, President – Biotechnology, Lupin Limited
BioVoice eMagazine June 2023 | Issue 6 | Volume 4
This edition tracks the latest scenario in Indian CRO industry and analyzes whether India can become a hotspot for clinical trials. Key highlights include Expert Insights by Dr Cyrus Karkaria, President- Biotechnology, Lupin and Zoya Brar, Founder, CORE Diagnostics.
Lupin Diagnostics expands footprint, sets up Regional Reference Laboratory in Indore
The launch of best-in-class regional reference lab in Indore marks its expansion into Central India
Lupin partners global agencies to increase patient access for tuberculosis prevention...
Makes Rifapentine based treatment available at an affordable price to support TB prevention in low-and middle-income countries